Cannabinoids May Help Manage Pain, but They Are Not a Proven Treatment for Opioid Use Disorder
Cannabinoids are being investigated as possible tools for managing chronic pain and reducing reliance on prescription opioids. But current evidence does not show that cannabis or cannabinoid products can replace established treatments for opioid use disorder (OUD).
A 2023 perspective published in the Harm Reduction Journal proposed an open-access clinical framework for using cannabinoids alongside opioid tapering and chronic-pain care. The authors focused on patients who are dependent on opioids, want alternatives, or are attempting to reduce their opioid dose.
The paper is a clinical framework and literature review—not a randomized clinical trial demonstrating that cannabinoids treat OUD. Its recommendations are intended to help clinicians standardize discussions about products containing compounds such as cannabidiol (CBD), tetrahydrocannabinol (THC), and other cannabinoids while more rigorous research is conducted.
The authors argue that cannabinoids could have a role in harm reduction, particularly for some patients with chronic pain who are already using cannabis or considering it as an alternative to opioids. However, evidence for pain relief remains limited and inconsistent. The Agency for Healthcare Research and Quality’s 2024 living systematic review found that available studies generally involve short-term treatment and provide insufficient evidence about whether cannabis reduces opioid use. Benefits appear most plausible for some neuropathic-pain conditions, but the overall effects are modest and products vary considerably in composition and dose.
Evidence on withdrawal and opioid use is similarly mixed. A systematic review of human studies found preliminary indications that cannabis or THC might ease some opioid-withdrawal symptoms, but the studies were highly heterogeneous. In the controlled trials, higher THC doses were also associated with effects such as tachycardia, dysphoria, and increased abuse liability. A separate 2024 meta-analysis of people receiving methadone, buprenorphine, or naltrexone found no significant association between cannabis use and subsequent nonmedical opioid use—neither supporting cannabis as an effective way to reduce opioid use nor showing that it consistently worsens treatment outcomes.
Population studies have also produced conflicting results. Some earlier research linked medical-cannabis laws or dispensary availability with lower opioid prescribing or overdose mortality. Later analyses, however, failed to consistently reproduce those findings, and associations between state policy and opioid outcomes cannot establish that cannabis access caused the changes.
Any opioid reduction plan should therefore be individualized and supervised. The CDC’s 2022 opioid-prescribing guideline advises clinicians not to abruptly discontinue opioids in patients who may be physically dependent. When tapering is appropriate, clinicians should work with patients, address pain and behavioral-health needs, manage withdrawal symptoms, and adjust or pause the taper when necessary.
For diagnosed OUD, the evidence-based standard of care remains treatment with FDA-approved medications—typically buprenorphine, methadone, or naltrexone—combined with appropriate behavioral and support services. Cannabis should not be used as a substitute for these therapies without medical guidance. The CDC specifically notes that there is no evidence that cannabis treats OUD and warns that using cannabis alone or with opioids may increase the risk of opioid misuse.
The 2023 framework identifies a question worth studying: whether carefully selected cannabinoid products might help some people manage pain or tolerate an opioid taper. It does not establish cannabinoids as a treatment for opioid dependence. Until stronger clinical evidence is available, their use should remain part of a cautious, patient-centered plan rather than a replacement for proven OUD treatment.
